Podcasts about Breakwater

Today's episode features a raw and refreshing chat with rising Irish music star Moncrieff. He stopped by the studio to talk about his whirlwind journey, the stories behind his songs, and what's in store for fans at his Breakwater show in Wexford this August. Expect honest moments, big tunes, and pure passion.

Today's episode features a raw and refreshing chat with rising Irish music star Moncrieff. He stopped by the studio to talk about his whirlwind journey, the stories behind his songs, and what's in store for fans at his Breakwater show in Wexford this August. Expect honest moments, big tunes, and pure passion.

**The Groove Doctors Friday Drive Time Show Replay On traxfm.org. This Week The Groove Doctor Featured 80's Grooves/Rare Groove/Contemporary Soul From Chapter 8. Midnight Star. Sasss. Rick James. Breakwater. Switch. Millie Scott. Heatwave. Loose Ends & More #originalpirates #soulmusic #boogie #80ssoul #RareGrooves Listen Live Here Via The Trax FM Player: chat.traxfm.org/player/index.html Mixcloud LIVE :mixcloud.com/live/traxfm Free Trax FM Android App: play.google.com/store/apps/det...mradio.ba.a6bcb The Trax FM Facebook Page : facebook.com/profile.php?id=10...100092342916738 Trax FM Live On Hear This: hearthis.at/k8bdngt4/live Tunerr: tunerr.co/radio/Trax-FM Radio Garden: Trax FM Link: radio.garden/listen/trax-fm/IEnsCj55 OnLine Radio Box: onlineradiobox.com/uk/trax/?cs...cs=uk.traxRadio Radio Deck: radiodeck.com/radio/5a09e2de87...7e3370db06d44dc Radio.Net: traxfmlondon.radio.net Stream Radio : streema.com/radios/Trax_FM..The_Originals Live Online Radio: liveonlineradio.net/english/tr...ax-fm-103-3.htm**

The ILB Team heads over to the CoLab Public House in Vista to meet Josh Avila, the new head brewer at Breakwater Brewing. They first met Josh tapping cask ale at Barley & Sword in North Park a year ago. Now Josh has taken on the Breakwater Brewing responsibilities and is finding the balance of staying true to the brand and bringing in his own creativity and insights. ILB hears about Josh's journey in San Diego beer and his vision for the future. Pull up a barstool and take a listen!

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable.  Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival.  The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen.  I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option.  So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Shaalan Beg  @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:    @ASCO on Twitter   @ASCO on BlueSky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Shaalan Beg:   Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

Watch This Episode On YouTubeJoining me today is…he is going to hate that I say it this way, as you'll hear in the conversation…but the director with the most nominated film at Raindance, Max Morgan, talking about his film BREAKWATER (2025).The ability to make your first feature, your first film, carry the weight of, and I'll quote Max here, “people never mean what they say, and there is a lot of that in BREAKWATER” is simply breathtaking. I've posted the trailer in the YouTube conversation, go watch it and you see what you mean. And the trailer is hardly encompassing of the beauty of the film.The film has its premiere at Raindance on June 23rd, 2025 — sold out — but tickets are still available for the 24th. Go watch it if you can. There's a reason it's the most nominated film, the first feature out of the University of Oxford since 1982, and that's Max Morgan and his team. In this episode, Max and I talk about:What people should expect to see when they watch BREAKWATER, such a wide ranging and expansive film — “it's a psychological drama about connection between two characters, Otto and an older retired angler on the East Coast of England…and it's about how their lives come together, collide through happenstance and fuse irreversibly and thematically”;How he decided to make such an ambitious film, the first film he ever shot! — “so it really was like a massive learning curve for me”; “and then when I went to university, I did lots of theater”;Was screenwriting a safety net for him? “ I find that thinking about myself as a writer is almost more important to me as thinking myself as a director in some ways”His advice for someone who is not gifted at writing and how to develop that skill without decades of education — “I don't think that being able to write a good play or screenplay is necessarily a gift. I think it's important to think about writing and directing in all kind of creative capacities as more of a craft.”His issues with the term debut film and filmmaker as “quite misleading”, as there's so much that goes into a creative's life;How mentors gave him advice on what he termed “bad plays, bad screenplays” — “ if anyone tells you as a piece of feedback that something is straight up bad, then they're really awful at giving notes”; How you have to trust your instincts as well — you have to challenge incredibly bad and incredibly good feedback equally;The realistic dialogue in BREAKWATER — was it from life experience? “It was from the theater”; “people never mean what they say, and there is a lot of that in BREAKWATER”BREAKWATER has its world premiere at Raindance — has he seen it on a cinema screen and does he see a theatrical run for the film?An interlude about the amazingness of Tom Cruise and his stunts;What does being a British filmmaker mean to him and how he thinks people think of that identity? “ the way I think about it is so massively influenced by British art and the sense of British independent filmmaking, which has historically produced so many amazing filmmakers”;How he is planning for the world premiere at Raindance;Max's Indie Filmmaker Highlights: Mark Jenkin, famously of BAIT (2019) and other films; Sarah BrocklehurstLinks:Buy Tickets To BREAKWATERFollow BREAKWATER On InstagramFollow BREAKWATER's WebsiteMax Morgan's WebsiteSupport this podcast at — https://redcircle.com/first-time-go/exclusive-content

En este programa especial, los Dres. Diego Ballén y Mauricio Lema, oncólogos clínicos colombianos, entrevistarán al Dr. Jorge Gallardo, oncólogo médico de la clínica Las Condes, Santiago de Chile, miembro de grupo de trabajo, SLAGO y presentarán lo más destacado en tumores gastrointestinales, presentado durante la Reunión Anual 2025 de la Sociedad Americana de Oncología Clínica, celebrada en Chicago, con base en la información disponible al momento de esta grabación.Los trabajos comentados son:CheckMate-577 (abstract #4000): estudio fase III, aleatorizado, multicéntrico, doble ciego, que evaluó nivolumab adyuvante en pacientes con cáncer de esófago o de la unión gastroesofágica resecado (R0) con enfermedad patológica residual después de quimiorradioterapia neoadyuvante. El objetivo primario fue la supervivencia libre de eventos (SLE). El objetivo secundario fue la supervivencia global (SG).MATTERHORN (abstract #LBA5): estudio fase III, aleatorizado, doble ciego y controlado con placebo, que evalúa la eficacia y seguridad de durvalumab, en combinación con quimioterapia FLOT (5-fluorouracilo, leucovorina, oxaliplatino y docetaxel) en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica resecable en estadio II o superior. El objetivo primario fue la SLE. Los objetivos secundarios fueron la SG y la tasa de respuesta patológica completa.DESTINY-Gastric04 (abstract #LBA4002): estudio fase III, multicéntrico, aleatorizado, abierto, que evalúa trastuzumab deruxtecan en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica metastásico o irresecable con HER2 positivo que han progresado durante o después de un régimen con trastuzumab. El objetivo primario fue la SG. Los objetivos secundarios, incluyen la supervivencia libre de progresión (SLP), la tasa de respuesta objetiva confirmada (TRO), la tasa de control de la enfermedad y la seguridad.ATOMIC (Abstract #LBA1): estudio fase III, aleatorizado y multicéntrico, que evalúa el uso de quimioterapia adyuvante con 5-fluorouracilo, leucovorina más oxaliplatino (FOLFOX) con o sin atezolizumab en pacientes con cáncer de colon en estadio III con inestabilidad de microsatélites (MSI-H, por sus siglas en inglés) o deficiencia en la reparación de errores de apareamiento de bases (dMMR, por sus siglas en inglés)). El objetivo primario fue la SLE. Los objetivos secundarios incluyeron la SG y el perfil de seguridad.BREAKWATER (abstract #LBA3500): estudio fase III, abierto, global y aleatorizado, que evalúa en primera línea el tratamiento con encorafenib más cetuximab, con o sin quimioterapia, frente al tratamiento estándar (quimioterapia con o sin bevacizumab) en pacientes con cáncer colorrectal metastásico con mutación BRAF V600E no tratados previamente. Los pacientes fueron asignados aleatoriamente en proporción 1:1:1 a recibir encorafenib más cetuximab, encorafenib más cetuximab y mFOLFOX6, o el tratamiento estándar. Los objetivos primarios fueron la tasa de respuesta objetiva confirmada y la SLP evaluadas por revisión central ciega, y como objetivo secundario se evaluó la SG.CHALLENGE (abstract #LBA3510): estudio fase III, aleatorizado que se diseñó para probar la hipótesis de que es posible lograr un aumento significativo de la actividad física recreativa después de la terapia adyuvante y que mejorará la SLE en el cáncer de colon en etapa 3 o en etapa 2 de alto riesgo. El objetivo primario fue la SLE comparada mediante una prueba de log-rank estratificada realizada sobre una base de intención de tratar. Los objetivos secundarios fueron la SG y los resultados informados por el paciente. ASCO® es una marca registrada de la American Society of Clinical Oncology. Este material ha sido producido de manera independiente y no está autorizado, patrocinado ni avalado por dicha organización.

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Cathy Eng, a renowned GI medical oncologist from the Vanderbilt Ingram Cancer Center, to discuss the most impactful updates from the ASCO 2025 annual meeting, specifically focusing on gastrointestinal (GI) malignancies. Join us as we dive into five pivotal abstracts that are set to change the landscape of GI cancer treatment: 1.⁠ ⁠DYNAMIC III: Discover how ctDNA-guided adjuvant chemotherapy in stage 3 colon cancer did not improve outcomes, highlighting questionable role of escalating approach with ctDNA positivity. 2.⁠ ⁠ATOMIC: Learn about the addition of atezolizumab to FOLFIRI in MSI-H disease stage 3 colon cancer, which improved disease-free survival with a hazard ratio of 0.50. 3.⁠ ⁠BREAKWATER: Explore how the combination of encorafenib, cetuximab, and FOLFOX has established a new standard of care for BRAF V600E mutant metastatic colorectal cancer, doubling overall survival from 15 months to 30.3 months. 4.⁠ ⁠MATTERHORN: Understand the use of durvalumab in the perioperative and postoperative setting with the FLOT regimen for resectable gastric and GE junction adenocarcinoma, showing significant improvements in event-free survival. 5.⁠ ⁠DESTINY Gastric04: Delved into the findings that confirm TDXd as a preferred option in the second line and beyond for HER2 positive metastatic gastric cancer or GE junction adenocarcinoma. YouTube: https://youtu.be/hllyI5S2Dqg Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Tune in for an insightful discussion that will keep you updated on the latest advancements in GI oncology! Don't forget to subscribe for more episodes on treatment algorithms, FDA approvals, and conference highlights.

In this episode of The Breakwater Podcast, we sit down with Kypton—a passionate young member of our youth substance use prevention group—and his mother, Megan, for a heartfelt conversation about the power of prevention, family, and community. Together, they share what it's been like to be part of Breakwater, how the group Substance Free Futures has shaped their journey, and why elevating youth voices is essential for creating positive change. Tune in for honest reflections and meaningful insights on how families and communities can come together to support youth in making healthy, substance-free choices.

Los Dres. Isabel Enríquez, Fernando Aldaco y Homero Fuentes, oncólogos médicos mexicanos, comparten su análisis de los estudios más relevantes presentados durante el primer y segundo día de la Reunión Anual 2025 de la Sociedad Americana de Oncología Clínica, celebrada en Chicago, con base en la información disponible al momento de esta grabación.Los trabajos comentados son:BREAKWATER (abstract #LBA3500)CheckMate 8HW (abstract #3501)CodeBreaK 300 (abstract #3540)Abstract #1014Abstract #1015INAVO120 (abstract #1003)DYNAMIC-III (abstract #3503)VERITAC-2 (abstract #LBA1000)ASCENT-04/KEYNOTE-D19 (abstract #LBA109)C-POST (abstract #6001)Fuentes:Abstracts presentados en el marco de la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO®) de 2025, Chicago, IL, EE.UU.Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud.Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados. ASCO® es una marca registrada de la American Society of Clinical Oncology. Este material ha sido producido de manera independiente y no está autorizado, patrocinado ni avalado por dicha organización.

**Lynda Law's Soul Show Replay On traxfm.org. This Week Lynda Features Soul/Boogie/Dance Classics/Contemporary Soul From Herbie Hancock, Breakwater, Meco, T-Connection, Bruno Mars, Bernard Edwards, Quincy Jones, Stevie Woods, Cameron, Bobby Thurston, The Whispers & More #originalpirates #soulmusic #contemporarysoul #70smusic #80smusic #disco #danceclassics Catch Lynda's Soul Show Every Tuesday From 4:00PM UK Time On www.traxfm.org Listen Live Here Via The Trax FM Player: chat.traxfm.org/player/index.html Mixcloud LIVE :mixcloud.com/live/traxfm Free Trax FM Android App: play.google.com/store/apps/det...mradio.ba.a6bcb The Trax FM Facebook Page : https://www.facebook.com/profile.php?id=100092342916738 Trax FM Live On Hear This: hearthis.at/k8bdngt4/live Tunerr: tunerr.co/radio/Trax-FM Radio Garden: Trax FM Link: http://radio.garden/listen/trax-fm/IEnsCj55 OnLine Radio Box: onlineradiobox.com/uk/trax/?cs...cs=uk.traxRadio Radio Deck: radiodeck.com/radio/5a09e2de87...7e3370db06d44dc Radio.Net: traxfmlondon.radio.net Stream Radio : streema.com/radios/Trax_FM..The_Originals Live Online Radio: liveonlineradio.net/english/tr...ax-fm-103-3.htm**

From Club Space to Regatta Grove, Emi Guerra has seen it all. We trace his journey from hustling in high school as a club promoter to launching iconic venues like Club Space, The Wharf, and Regatta Grove. Emi opens up about the rollercoaster ride of entrepreneurship — the early struggles, near-collapse, and the eventual rise of Breakwater Hospitality.It's a raw, insightful look at what it takes to build Miami's most memorable nightlife and hospitality experiences and a powerful reminder that you don't fail until you quit.Connect with usWant to dive deeper into Miami's commercial real estate scene? It's our favorite topic—and we're always up for a good conversation. Whether you're just exploring or already making big moves, feel free to reach out at felipe@builtworldadvisors.com or give us a call at 305.498.9410. Prefer to connect online? Find us on LinkedIn or Instagram—we're always open to expanding the conversation. Ben Hoffman: LinkedIn Felipe Azenha: LinkedIn We extend our sincere gratitude to Büro coworking space for generously granting us the opportunity to record all our podcasts at any of their 8 convenient locations across South Florida.

Send us a textWelcome to The Oncology Journal Club Podcast Series 3! Proudly produced by The Oncology NetworkThree respected oncologists dive deep into the most significant research presented at ASCO GI 2025, bringing you practice-changing insights amidst a backdrop of political uncertainty affecting medical research.Professor Chris Karapetis joins hosts Professor Craig Underhill and Professor Christopher Jackson to unpack ground-breaking colorectal cancer studies that are reshaping treatment paradigms. The conversation explores how targeted therapies are dramatically improving survival rates, with the DEEPER study demonstrating cetuximab's superiority over bevacizumab for left-sided RAS wild-type disease, achieving an impressive 50-month median survival when combined with chemotherapy.The experts dissect the BREAKWATER trial, which shows promising benefits of combining encorafenib and cetuximab with chemotherapy for notoriously aggressive BRAF-mutant colorectal cancer. This combination achieved a 61% response rate versus 40% with standard care, with responses lasting significantly longer – representing a potential new standard of care for this difficult-to-treat subgroup.Perhaps most surprisingly, our panel discusses how an inexpensive, familiar medication – aspirin – could reduce colorectal cancer recurrence by 40% in patients with PIK3CA mutations according to the ALASCCA study. This finding highlights how molecular profiling is becoming essential across treatment stages, not just for expensive targeted therapies but also for optimising use of accessible interventions.The discussion extends to exciting developments in pancreatic cancer with a novel pan-RAS inhibitor showing meaningful activity, and advancements in immunotherapy for MSI-high colorectal cancer, confirming combination therapy's superiority. For gastrointestinal oncologists navigating an increasingly complex treatment landscape, this episode offers crucial insights to optimise patient outcomes through precise, personalised approaches.Subscribe to The Oncology Newsletter for regular updates on the latest cancer research and join our community at oncologynetwork.com.au.The Oncology Podcast - An Australian Oncology Perspective

Surging seas and boulders regularly cut off people living on Trepassey's lower road. The town's brand new breakwater was swept away last year... and since then residents feel adrift. We reach the mayor of Trepassey to hear about the breakwater problems... and unkept promises. (Krissy Holmes with Rita Pennell)

Katie Jaegly from UW Extension joins the podcast to share some of her experiences and what she does and also her involvement with Substance Free Futures.

**The Groove Doctors Friday Drive Time Show Replay On traxfm.org. This Week The Groove Doctor Featured 80's Grooves/Rare Groove/Contemporary Soul From Selection Of Tracks From Merry Clayton. Breakwater. Harvey Mason. M.C.B. Jean Carne. William C Brown lll. The Pointer Sisters. Randy Brown. Little Beaver. Freddie Hubbard. Numonics & More #originalpirates #soulmusic #boogie #80ssoul #RareGrooves Listen Live Here Via The Trax FM Player: chat.traxfm.org/player/index.html Mixcloud LIVE :mixcloud.com/live/traxfm Free Trax FM Android App: play.google.com/store/apps/det...mradio.ba.a6bcb The Trax FM Facebook Page : facebook.com/profile.php?id=10...100092342916738 Trax FM Live On Hear This: hearthis.at/k8bdngt4/live Tunerr: tunerr.co/radio/Trax-FM Radio Garden: Trax FM Link: radio.garden/listen/trax-fm/IEnsCj55 OnLine Radio Box: onlineradiobox.com/uk/trax/?cs...cs=uk.traxRadio Radio Deck: radiodeck.com/radio/5a09e2de87...7e3370db06d44dc Radio.Net: traxfmlondon.radio.net Stream Radio : streema.com/radios/Trax_FM..The_Originals Live Online Radio: liveonlineradio.net/english/tr...ax-fm-103-3.htm**

Dr. Shaalan Beg and Dr. David Wang discuss key abstracts in GI cancers from the 2025 ASCO Gastrointestinal Cancers Symposium, including major advances in CRC, neoadjuvant approaches in esophageal cancer, and innovative studies on ctDNA. TRANSCRIPT Dr. Shaalan Beg: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas. Today, we're bringing you some key highlights from the 2025 ASCO Gastrointestinal Cancers Symposium, and I'm delighted to be joined by the chair of GI25, Dr. David Wang. Dr. Wang is a GI medical oncologist at the University of Michigan. Our full disclosures are available in the transcript of this episode.  Dr. Wang, thanks for coming on the podcast today. Dr. David Wang: Well, thank you. It's a pleasure to be here. Dr. Shaalan Beg: GI25 featured major therapeutic advances across the spectrum of GI malignancies, and it was exciting to hear about innovations and novel approaches that are shaping the future of our field. Before we start talking about specific abstracts, could you share some of your key highlights from the meeting? Dr. David Wang: Sure. Our theme this year was “Breaking Boundaries to Enhance Patient Centered Care.” Past years' themes have focused more on precision oncology, but we wanted to broaden our focus on patients and to be more holistic, which kind of led us into some of the Intersection [sessions] that we had. Each day started with a different Intersection. The first one was “Emerging Therapies in GI Cancers”, where invited speakers talked about bispecific antibody drug conjugates, theranostics, CAR T and other cell-based therapies. The second day was on “Personalized Risk Assessment for GI Cancers,” and this included looking at polygenic risk scores for colorectal cancer, microRNAs and liquid biopsies such as exosomes and pancreatic cancer and non-endoscopic screening modalities in esophageal cancer. And on our final day, we wanted to talk about “Integrative Oncology and Integrative Medicine,” looking at evidence-based uses of acupuncture and supplements in patients who are receiving treatment for cancer, mindfulness-based practices and exercise. And of course, we had a fantastic keynote talk by Dr. Pamela Kunz from the Yale School of Medicine titled, “Disrupting Gastrointestinal Oncology: Shattering Barriers with Inclusive Science.” She highlighted the intersection of science, patient care, and health and gender equity. And I would encourage your podcast listeners to access the lecture in ASCO's Meeting Library if they haven't yet had a chance to hear Dr. Kunz's wonderful lecture.  We were really happy this year because the attendance hit a new record. We had over 5,000 people attend either in person or virtually from their home or office, and we had almost 1,000 abstracts submitted to the meeting, so these were either record or near record numbers. We offered a lot of different networking opportunities throughout the meeting, and attending found these to be incredibly rewarding and important and this will continue to be an area of emphasis in future meetings. Dr. Shaalan Beg: Let's take a deeper dive into the exciting studies presented at GI25. The late breaking abstract LBA143 was CheckMate-8HW. This was the first results of NIVO + IPI versus NIVO monotherapy for MSI-high metastatic colorectal cancer. What are your thoughts about this study? Dr. David Wang: Yeah, so we know that colorectal cancer patients with MSI-high tumors don't necessarily respond well to chemotherapy. And we were fortunate because last year CheckMate-8HW actually looked at two different arms – so this was NIVO + IPI compared to standard of care chemotherapy and showed its very significant improvement in median progression-free survival. And that was actually published in the New England Journal of Medicine back in November of 2024. This year's presentation actually focused now on NIVO + IPI versus NIVO monotherapy. And as you know IPI+NIVO can be quite toxic. So this was an important analysis to be done. So we know that NIVO is definitely more easily tolerated. So what was interesting was that the 2-year and 3-year progression-free survival not surprisingly favored IPI+NIVO and this was statistically significant. And the overall response rate was also better with IPI+NIVO versus NIVO alone. I know we're always concerned about toxicities and there were higher grade 3 and 4 toxicity incidences in the combination arm versus the monotherapy arm, but overall, only about 28 additional events in several hundred patients treated. So I think that's well-tolerated. Our discussant Dr. Wells Messersmith actually said that, with this new data, he would consider doing combination immunotherapy in any patient that presented in the front line with MSI-high or deficient mismatch repair colorectal cancer that was metastatic. Dr. Shaalan Beg: One of the focuses for directing first-line therapy for colorectal cancer has been right and left sided colon cancer because we know these are two different cancers with their own unique molecular subtypes. We heard on Abstract 17, the DEEPER trial, the final analysis of modified FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left sided metastatic colorectal cancer. How do you summarize the findings of this study and what should our readers be aware of? Dr. David Wang: Interestingly, this was a phase 2 study and the emphasis of the abstract was actually a subgroup analysis of those patients with RAS wild-type and BRAF wild-type as well as left sided cancers. So, I think the entire study enrolled 359 patients, but the analysis that was discussed at the meeting really focused on 178 patients that fit that characteristic. Very similar to what we've seen in prior studies, left-sided tumors have better response to cetuximab versus bevacizumab. And if you flip it so that you now are looking at right sided tumors, targeting EGFR is actually detrimental. The depth of response was better with cetuximab in these left sided RAS and BRAF mutant tumors. And so the lead author actually suggested that this could be a new first-line standard of care. And the question is, is there a benefit of doing this triple agent regimen with modified FOLFIRINOX? We know there's a lot more toxicity with that. Not clear that there's a benefit for that over FOLFOX, maybe in younger patients that could tolerate it. When our discussant, again Dr. Wells Messersmith, spoke about this, he said that, in his practice he would, again, favor cetuximab over bevacizumab in combination with chemo, these left-sided RAS and BRAF wild-type tumors, but that he would actually prefer a doublet versus a triplet chemo regimen, and that is consistent with the current NCCN guidelines. Dr. Shaalan Beg: Another area where colorectal cancer has been a wonderful model to study new technology has been in the area of circulating tumor DNA (ctDNA). And the BESPOKE CRC trial is looking to see if ctDNA can inform adjuvant treatment decisions for stage II and III colorectal cancer. And in Abstract 15, we heard final results of the BESPOKE CRC sub-cohort. What were the findings there? Dr. David Wang: BESPOKE CRC is another one of these important ctDNA studies. It was an observational study, not a randomized trial, but it did provide a lot of different insights to us. We know that there were over 1,700 patients enrolled, and so it was reported that this is the largest ctDNA study in colorectal cancer performed in the United States. And they were able to analyze over 1,100 patients.  Some of the key findings were that postoperative adjuvant therapy management decisions actually changed in 1 out of 6 patients, so that's pretty significant. In terms of surveillance, we know that patients who have ctDNA positivity, this is prognostic of recurrence. In terms of patients who have positive ctDNA post-surgery, it looked like, at least in this observational study, the majority of patients who received any benefit were those who had positive ctDNA. So adjuvant therapy, even in stage II and stage III patients seemed to only benefit those patients who have positive ctDNA. I think that does raise the question, and this also was brought up in the discussion, which is “Can we de-escalate adjuvant therapy in terms of patients who are ctDNA-negative post-op?” And Dr. Richard Kim from Moffitt felt that we are not yet there. Obviously, we need randomized control trials where we are taking ctDNA results and then randomizing patients to receive adjuvant or non-adjuvant to really know the difference.  Other questions that come up with use of ctDNA include: What do you do with these patients who turn positive? This study for BESPOKE actually followed patients out to two years after surgery. So what you do with a positive ctDNA result wasn't really clear. It seems to suggest that once you turn positive, patients go on to more intensive surveillance. You know, again as an observation, patients who did turn positive were able to go to metastasis-directed therapy much more quickly. And again, this was supposedly to improve their curative intent therapy. And I think the other question that has been brought up all the time is, is this really cost effective? Patients want to know, and we want to give patients that information, but I think we're still stuck with what to do with a positive ctDNA level in a patient that's on surveillance because no randomized control studies have actually suggested that we need to start systemic therapy right away. Dr. Shaalan Beg: Yeah. And I guess in terms of practice informing or practice changing, these results may not give us a clear answer. But because a lot of patients are asking for these tests, it does give us some real world experiences on what to expect in terms of conversion of these positive into negative and the outcome so we can have a shared decision making with our patients in the clinic and then come up with a determination on whether ctDNA for molecular residual disease is something which would be worthwhile for the care of our patient. But more to come, I guess, in coming years to answer different problems around this challenge. Dr. David Wang: Yes, I agree. Dr. Shaalan Beg: The BREAKWATER trial looked at the use of encorafenib, cetuximab and chemotherapy for BRAF V600E-mutant metastatic colorectal cancer. We've covered this combination for a second- third-line treatment in metastatic colorectal cancer previously. Abstract 16 from GI25 was evaluating the use of this regimen in the first-line space. Everyone was looking forward to these results, and what did the investigators present? Dr. David Wang: I think this is, as you mentioned, a nice follow up to later lines of therapy where Dr. Kopetz from MD Anderson pioneered use of encorafenib, cetuximab and binimetinib in the BEACON trial. Everybody was kind of curious what would happen now if you use encorafenib plus cetuximab plus chemotherapy in the first-line setting. And so this is an interim analysis that was pre-planned in the phase 3 open label BREAKWATER trial. And even though there were three arms, and so the three arms were encorafenib plus cetuximab, encorafenib plus cetuximab plus FOLFOX, or standard of care chemo, only two arms were presented in the abstract. So basically looking at encorafenib plus cetuximab and FOLFOX-6 versus standard of care therapy, and the overall response rate was statistically significant with a 60.9% overall response rate encorafenib plus cetuximab plus chemo arm versus standard of care chemo was only 40%. The interim overall survival also was different. It was 92% versus 87% at 6 months and 79% versus 66% at 12 months, again favoring the chemotherapy plus encorafenib plus cetuximab. In terms of the statistics, the p was 0.0004. However, the pre-plan analysis required the p-value to be 1x10 to the -8. And so even though this looks really good, it hasn't quite met its pre-specified significance level. The good thing is that this is only interim analysis and the study is ongoing with future analysis planned.  So the real question is: Does it matter when we actually use this regimen? We know that the regimen's approved in the second third-line setting. What about in the first line? And there was some preclinical data that the discussant reviewed that shows that patients actually benefit if this is done in the first-line setting. For example, there was some preclinical data showing that even FOLFIRI, for example, can upregulate RAS, which would make tumors more resistant to this combination. This was thought to be practice-changing in a patient that has B600E showing up treatment naive that we should probably consider this regimen. And actually this did receive accelerated FDA approval about a month ago. Dr. Shaalan Beg: Yeah, and for what it's worth, I put up a Twitter poll asking my Twitter followers on how the BREAKWATER trial results will change their approach for newly diagnosed BRAF mutated colorectal cancer. We got 112 responses; 72% said that they will incorporate encorafenib, cetuximab, FOLFOX for their frontline BRAF mutated patients. But 23% said that they would like to wait for overall survival results. Dr. David Wang: Wow, that's interesting. They really want that 1x10 to the -8. Dr. Shaalan Beg: I guess so. All right. Let's change gears and talk about esophageal cancer. LBA329 was the SCIENCE study which presented preliminary results from a randomized phase 3 trial comparing sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant resectable locally advanced squamous esophageal cancer. Where are we in this space? Dr. David Wang: Okay. So, yeah, this was an interesting trial. Again, just to set the context, esophageal squamous cell carcinoma is more prevalent in Asia. And the study sites as well as the patients were mostly from Asia. So this was again a phase 3 trial with interim results. They only rolled 146 out of the planned 420 for this interim analysis. And yeah, they're using immune checkpoint inhibitor that we don't use in the United States, sintilimab, combined with their two standards of neoadjuvant therapy, either chemotherapy, which is more common in Asia, or or chemoradiation, which is more common in the US and Western Europe, versus chemoradiation. And so they actually had two primary endpoints, but only were reporting one. So their two primary endpoints were pathCR and the other one was event-free survival. The event-free survival, again, was not reported at the meeting.  What they found was that in terms of pathCR rate, if you take the two arms that are really informative about that, chemoradiation plus sintilimab versus chemoradiation alone, the pathCR rate was 60% versus 47%. We know that chemo alone doesn't induce as much of a pathCR rate, and that was 13%. So it was found that the delta in terms of pathCR between the chemoradiation arms, one with sintilimab and one without, was significant. And this actually confirms data again from Asia, like for the ESCORT-NEO trial where it used another immune checkpoint inhibitor pembrolizumab in addition to neoadjuvant chemo.  So as our discussant for this abstract said, yes, we know that radiation combined with chemotherapy improves pathCR rates, but we have recent data from the ESOPEC trial, we don't know that that necessarily will translate to overall survival. So again, waiting for additional enrollments and longer term follow up before incorporating this into clinical care here. Dr. Shaalan Beg: So David, how do the results of the SCIENCE trial compare with our practice in the United States and ongoing studies asking questions for neoadjuvant therapy for esophageal carcinoma in the United States? Dr. David Wang: I think obviously immune checkpoint inhibitor in the new adjuvant setting is important. Jennifer Eads at UPenn is running that EA2174 which is looking at chemoradiation plus or minus nivolumab, and then in non-pathCR responders randomized to adjuvant nivolumab per CheckMate 577 or nivolumab with intensification adding ipilimumab. We know that the ESOPEC trial just came out, and was published actually during the meeting, and that really focuses on adenocarcinomas. So adenocarcinomas of the GE junction, distal esophagus, now, we would probably treat very similarly to gastric using perioperative FLOT. However, the standard in the US for esophageal squamous cell carcinoma remains neoadjuvant chemoradiation. We know that squamous cell carcinomas are more exquisitely sensitive to radiotherapy. And then obviously in those patients who don't achieve a pathologic complete response, the expectation would be that they would go on to receive nivolumab per CheckMate 577. Again, the thought is that these tumors are more sensitive to immunotherapy given their higher incidences of mutational changes. And so again, this kind of goes along with the positive results seen in the SCIENCE trial that we just discussed with sintilimab but also EFFECT-neo with pembrolizumab. Obviously, we await the results of Jennifer's trial. Dr. Shaalan Beg: And the last abstract I was hoping we could get your perspective on was Abstract 652, which is a Phase 3 study of everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumors, the STARTER-NET trial. What were the results of this study? Dr. David Wang: So, I just want to give a shout out because we did have a session at this year's GI ASCO that looked at more rare tumors. So appendiceal tumors, neuroendocrine tumors, those kinds of things. So again, I would encourage your listeners to listen to that session if they have interest in that. Another type of rare tumor was adenosquamous tumors.  But in terms of the STARTER-NET trial, this was again an interim analysis of his phase 3trial and it was looking at combining everolimus plus lanreotide versus everolimus. So we know that in pancreatic-gastric neuroendocrine tumors, if you have low Ki-67, a well differentiated tumor, that the standard of care really is a somatostatin analog, and sometimes if they're more aggressive, we kind of consider molecular targeted therapy with everolimus. This was asking the question of whether we should do the combination on the frontline. And what was interesting is in this study, the patients were actually more of a poor prognostic set. So they had Ki-67 up to 20% or these were patients that actually had multiple liver lesions. And what they found was a median for progression free survival was improved with a combination out to 29.7 months versus 11.5 months with the somatostatin analog alone, and that the overall response rate was 23% versus 8.3%, again, favoring the combination. If you looked at subgroup analysis, it was actually those patients who had Ki-67 greater than 10%, so the more aggressive tumors, or those with diffuse liver lesions that had the most benefit. So I think that would be the patient population I would consider this new combination with using would be those patients again with poorer prognosis neuroendocrine tumor phenotype. Dr. Shaalan Beg: Thank you very much, Dr. Wang, for sharing your insights with us today and your great work to build a robust GI Cancers Symposium this year. Dr. David Wang: Well, thank you. I mean that really is a cooperative effort. We appreciate all the members of the GI25 Program Committee as well as the ASCO staff that just made it an outstanding meeting. Dr. Shaalan Beg: And thank you to all our listeners for your time today. You'll find links to the abstracts discussed today on the transcript of this episode.  Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. Shaalan Beg @ShaalanBeg  Dr. David Wang Follow ASCO on social media:   @ASCO on Twitter  @ASCO on BlueSky ASCO on Facebook   ASCO on LinkedIn   Disclosures:  Dr. Shaalan Beg:  Employment: Science 37  Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine  Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals  Dr. David Wang: Honoraria:  Novartis Consulting or Advisory Role: Novartis, Cardinal Health, Bristol-Myers Squibb, BeiGene, Eisai  

I've got the Estuary Tour Save the date and the BW Exchange Germany Flyer attached as PDF's and have the links for the RSVP and Exchange ticket website below: Estuary Tour RSVP: Estuary Tour RSVP https://docs.google.com/forms/d/e/1FAIpQLSeB3ffRphBA8QH844v6K0KdcyaDnRfeX9IF-9zZGpFZixNIQA/ Breakwater Exchange Germany Ticket Page: Buy tickets – Breakwater  https://www.tickettailor.com/events/breakwater/1518547  Exchange - Deutschland 2025 – Wird bald bekanntgegeben Let me know if that will work for you. If you like you can also provide the BW email as well: contact.breakwater@gmail.com   Christ and Culture event Saturday Feb 15 2025 Galway Ireland https://www.eventbrite.ie/e/christ-and-culture-tickets-1104448638609    Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/KEPbZT28 https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://calendly.com/paulvanderklay/one2one There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640 https://www.livingstonescrc.com/give  

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Alok Khorana, a GI medical oncologist from the Cleveland Clinic, to discuss the latest highlights from the GI ASCO 2025 conference. We dive into four key studies that are practice-informing and potentially practice-changing: 1. BREAKWATER: We explore the implications of using Encorafenib and Cetuximab in combination with FOLFOX for patients with BRAF V600E mutations, which are associated with poor prognosis. 2. CheckMate-8HW: This study investigates whether dual checkpoint inhibition is more effective than single-agent immunotherapy for MSI-high patients, revealing promising results in progression-free survival. 3. Aspirin in Adjuvant Settings: We discuss the role of low-dose aspirin in reducing recurrence rates for patients with PI3K alterations, highlighting its potential as a practice-changing intervention. 4. STARTER-NET: Finally, we review the findings from the study on Everolimus combined with Lanreotide for neuroendocrine tumors, noting the lack of overall survival benefit. Tune in for an insightful discussion on these important topics in oncology, and learn how these findings could impact treatment strategies in your practice. Don't forget to like, subscribe, and check out our other episodes for more conference highlights and treatment discussions! YouTube: https://youtu.be/YOToz3hKYTg Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers #OncologyBrothers #GIASCO2025 #ColorectalCancer #Immunotherapy #NeuroendocrineTumors #CancerResearch #Podcast

We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.

Lead Time listeners, Tim Ahlman here! We love bringing you content to grow as leaders in your ministry and beyond, but we want to make sure we're hitting the mark. Can you help us out by filling out a quick 5-question survey? It'll take less than a minute and help us know what you like about the podcast, what topics you want more of, and even which guests you'd love to hear from next.https://www.surveymonkey.com/r/LeadTimePodcastThe episode highlights the innovative ministry of Pastor Ed Doerner, who shows how churches can effectively engage communities by addressing what they need help with! Through initiatives like a car repair garage and grocery store, Pastor Ed illustrates the importance of dignity and sustainable models in outreach, encouraging churches to expand their missions beyond conventional practices. • Pastor Ed Doerner's journey of innovative ministry • Addressing transportation challenges through affordable car repairs • The impact of running a grocery store on community dignity • Importance of serving the ALICE population in ministry • Engaging the community through volunteerism and participation • The eight core needs of communities: housing, transportation, food, childcare, jobs, healthcare, recovery, and community • Trusting in God's provision when stepping beyond comfort zones • Encouragement for churches to embrace missional outreach strategiesSupport the showJoin the Lead Time Newsletter! (Weekly Updates and Upcoming Episodes)https://www.uniteleadership.org/lead-time-podcast#newsletterVisit uniteleadership.org

Every new author has things to learn, but there are some major mistakes early on that some make over and over again. Eight authors reveal them so that you can avoid making them yourself!Featuring, from Engen Books:Matthew Daniels, author of InterstichesJRH Lawless, author of Always Greener From Flanker Press:Ida Linehan Young, author of A Secret Close to Home From Breakwater Books:Paul David Power, author of CrippledDr Richard Elcock, contributor to Us, NowMichelle Porter, author of Approaching FireOlivia Robinson, author of The Blue Moth Motel, and more!Originally broadcast on December 2, 2024 on CHMR 93.5 FM in St. John's, and on other great stations across the country. Check out As Loved Our Fathers, the latest book from Write Project host Matthew LeDrew: https://amzn.to/3HB7BABIt's a hunt for the Holy Grail taken on by an American Anthropologist and a Newfoundland History professor that unveils hidden secrets within Newfoundland history! Support the showProduced and recorded at CHMR 93.5 FM in St. John's, Newfoundland. Listen on CHMR online at http://www.chmr.ca/​This program is sponsored by:Engen Books: Checkout Engen titles at http://www.engenbooks.com/​Or sign up for their newsletters at: The Write Project signup for FREE book: http://eepurl.com/c8W9OTEngen Horror Society Signup for FREE book: http://eepurl.com/c8YemrFantasy Files signup for FREE book: http://eepurl.com/c8X4zLEngen's Science-Fiction Newsletter for FREE book: http://eepurl.com/ir5JmgThis recording copyright © 2024 Matthew LeDrew

Manitowoc North Breakwater Lighthouse, USLHS photo by Tom Tag The city of Manitowoc, Wisconsin, is on the west shore of Lake Michigan, at the mouth of the Manitowoc River. The Manitowoc North Breakwater Lighthouse, built in 1918, is one of the area's most familiar icons. The lighthouse property was auctioned by the federal government in 2010 under the guidelines of the National Historic Lighthouse Preservation Act. The buyer was Philip Carlucci of Melville, New York. Courtesy of the Manitowoc Sunrise Rotary Club Since he's owned the lighthouse, Phil Carlucci has been responsible for much restoration. He has now partnered with the Manitowoc Sunrise Rotary Club to offer public tours of the lighthouse. Members of the club keep the building clean and offer tours on a regular basis. Interviewed in this podcast episode are three board members of the Manitowoc Sunrise Rotary Club:  Paul Roekle, Dennis Huckins, and Mike Woznick. Manitowoc North Breakwater Lighthouse soon after it was constructed (National Archives)

HERE WE GO MY SHOW FOR 14-NOV-2024 WITH A MIXED BAG OF OLD CLASSICS INCLUDING ( EARTH WIND & FIRE, WEBSTER LEWIS, JUICY, DENNIS EDWARDS, JEAN CARN, BREAKWATER, STEVIE WONDER, MELBA MOORE  ) AND MANY MORE ALSO SOME TOP NEW TRACKS FROM ( LOUISE MEHAN/KATHY KOSINS, JULIAN JONAH/ROBBY LOVE, MATHER ) WE ALSO HAVE THE CONNOISSEURS CORNER ( THIS WEEK WE HAVE  TRACKS FROM HIROSHI FUKUMURA AND B BAKER CHOCOLATE CO  ) AND WE HAVE THE BACK TO BACK CLASSICS BY A CLASSIC ARTIST (THIS WEEK WE HAVE TWO TRACKS FROM PHYLLIS HYMAN ) THEN WE HAVE THREE TRACKS DUG OUT FROM THE GARAGE FROM MARVIN GAY & TAMMI TERRELL TWO SONGS , MARVIN GAY & KIM WESTON ) FINNISHING OF WITH A COUPLE OF SLOW TRACKS AND MUCH MUCH MORE SIT BACK WITH A GLASS OF SOMETHING AND ENJOY OR DOWNLOAD FOR LATER

In this episode, Avery Hill Publishing's Ricky Miller talks to Katriona about the cultural influences on her work in comics. Kat picks a favourite book, play, film, comic, and TV show to discuss. The post Signals From The Hill #59 – Katriona Chapman (author of ‘Breakwater' and ‘Follow Me In') about the cultural influences on her work in comics appeared first on Avery Hill Publishing.

Learn about the new wave of Breakwater a youth substance use prevention coalition.

Today on Art of the Cut, we discuss Michael B. Jordan's directorial debut, Creed III, with the editors of the film, Jessica Baclesse and Tyler Nelson, ACE. Jessica is currently editing the film Rez Ball. She was an assistant editor on Captain Marvel, has edited numerous short films, and the TV series, Breakwater, Play By Play and In the Vault. Her commercial editing work has been nominated for numerous awards. Tyler  has been on Art of the Cut several times, including for his work as an editor on The Batman and the TV series Mindhunter. He also edited TV series including Love, Death and Robots, Shadow and Bone and Tales from the Loop. As an assistant editor, he worked on Gone Girl and The Social Network and the TV series House of Cards. If you want to read along with the podcast and see some great exclusive images and clips from the movie, check out the Art of the Cut blog on BorisFX at: borisfx.com/blog/AOTC.

Racine County boasts a diverse landscape of cities, villages, and towns, offering a blend of urban and rural experiences. In this episode, we delve into the rich history and Danish heritage of Racine, home to the renowned O&H Danish Bakery, and explore its active arts community and educational initiatives, such as the Ardagh Glass Company's partnership with Burlington's STEM program. Recognized for its vibrant downtown scene, Racine has earned accolades for events like First Fridays and the Party on the Pavement, while Burlington hosts the lively Jamboree and Experience Burlington Days. Outdoor enthusiasts can revel in the natural beauty of Lake Michigan at North Beach and partake in activities like the Aquaducks water skiing show at Brown's Lake. Additionally, the county offers a plethora of recreational amenities, from parks like Jonathan - Pritchard Park to attractions like the Racine Zoo and dining establishments ranging from Well Brothers Pizza to Fred's Burgers. Economic development initiatives, such as the Microsoft Data Center and Breakwater 233, underscore the county's commitment to growth and prosperity.Learn more about Racine County here:Racine County: https://bit.ly/4aCHlBFExplore Burlington: https://bit.ly/4550P0zRacine Downtown: https://bit.ly/4dQTbeeVisit Racine County: https://bit.ly/4azmGP3Explore Waterford:https://bit.ly/4aJIoQiSponsored By: Racine County: https://bit.ly/4aCHlBF

For IROs, it is more important than ever to understand strategic trajectory, market position, and risk management for their companies. In today's episode, Mark Fasken sits down with Mark Hayes, Partner and Head of Capital Markets Advisory at Breakwater Strategy, to discuss the evolving role of the elevated IRO, the significance of collaboration across functions for effective IR. and how IR can use impact intelligence to customize approaches and gather relevant insights for decision-making and valuation. Listen to the full episode to learn more about:Defining the Elevated IROThe six essential skills of an Elevated IROIdentifying skill gaps and opportunitiesAn introduction to impact intelligence and it's impact and use casesNext steps for Elevated IROsWinning IR is brought to you by Irwin. For more winning ideas, subscribe to Winning IR wherever you get your podcasts.For more information, visit getirwin.com/winning-ir

https://buttickets.at/breakwater/1242831 https://tinyurl.com/BreakwaterDiscord breakwater@gmail.com   July 5 to 7 Leusden, The Netherlands   Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/JpHtVgXW https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://calendly.com/paulvanderklay/one2one There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640

Introducing Jake from Vive 18 – an exciting opportunity to discover the latest initiatives in our community focusing on drug prevention for young teens. Tune in to hear about the incredible advancements and impactful movements spearheaded by our youth! Get ready to be inspired!

Rhys Laverty writes about the Alderney Breakwater, a crumbling jetty in the Channel Islands that protects a way of life.

In this episode Nataraj talked to Peter Mueller who is the founding partner of Breakwater ventures investing in early stage tech startups in Pacific Northwest and Wester Canadian Startups. The conversation includes: - how to think about angel investing & pre-seed investing? - Seattle pre-seed ecosystem - learnings from Seachange fund - thesis for breakwater - Whats making Western Canada an interesting place to invest? - investing in AI - long tail opportunity in AI & more. Follow peter on twitter here - https://twitter.com/pjsmueller Follow Nataraj on twitter here - https://twitter.com/natarajsindam Follow 100 Days of AI here - https://thestartupproject.io/100-days-of-ai/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/startupproject/message

On a blustery day, Canadian - and even more geographically specific - Victoria author Jean Paetkau talks about her book "Blood on the Breakwater". Paetkau reveals the title of her upcoming sequel is "The Sinking of Souls" with a storyline that also is based locally. To be released in September 2024 you will find it on Amazon and local booksellers like the elegant and acclaimed Munro's on Government Street and Bolen Books in the Hillside Centre. Have a listen to this conversation which also delves into the writing process.

Today, we invite you into the captivating world of Erin Keating, a dynamic powerhouse who has climbed the ranks from the film industry to Snapchat, where she led the charge on original mobile shows. Now, Erin is on the cusp of a new chapter, carving out her own path with her raw and honest podcast, "Hotter than Ever." In today's episode, headlined by the empathetic and probing questioning of our host, Reena Friedman Watts, alongside the sagely insights of Wayne Friedman, fondly known as "dad" or "grandpa," we dive deep into Erin's multifaceted journey. Erin bravely shares her inner turmoil over being a corporate spokesman, her craving for self-expression, and her dream of forging a media empire on her terms. As we peel back the layers of Erin's transition from a corporate executive to a champion for authentic storytelling for Gen X women, we confront the conventional self-help narratives. Erin opens up about the personal and professional pivots she's navigated – from her New York artistry and TV executive triumphs to the introspection spurred by a tumultuous marriage and an eye-opening battle with Covid. We'll journey through her bold post-divorce rediscovery and her insightful approach to dating, punctuated with humor, self-compassion, and a rejection of the patterns tied to upbringing and societal pressures. Erin's tale is one of rebirth, a testament to the power of reimagining one's life even in the face of deep-seated challenges. So, join us for a heart-to-heart with Erin Keating, an unfiltered reflection on desire, resilience, and the uncharted waters of self-empowerment. You're listening to "Better Call Daddy," and this is the episode you don't want to miss. Don't forget to like, subscribe, and share as we delve into a story that will leave you inspired, enlightened, and undoubtedly ready to carve out your own path in honesty and self-expression. Erin Keating is an award-winning television development and production executive and single Mom to twin tweens living in Los Angeles. With her eyes on the wider content landscape, Erin created Hotter Than Ever to produce media that reflects the authentic, messy, sexy, funny and inspiring stories of women over forty. Erin's passion for smart, brand-defining original programming has led to zeitgeist-shaping shows like Portlandia, along with the first-ever made-for-mobile scripted series.  Her career has included senior creative roles at Snapchat, Big Beach TV, IFC TV and Magna Global Entertainment.  She climbed the television ladder at BBC America, NBC and Comedy Central. Recent shows created under Erin's watch have included the Emmy-winning James Corden's Next James Corden, the WGA Award winning drama Class of Lies, the WGA Award nominated thriller Breakwater and the NAACP Image Award-nominated Two Sides. Erin also conceived the drama Vida (Starz), produced the documentary Fatherless (Fusion), and executived the hell out of the iconic sketch series Portlandia (which won a Peabody and a bunch of other fancy statues) along with other comedy, dramedy and animated series. Erin grew up in the basement theaters of downtown NYC, where she produced and performed in live comedy shows at venues like The Slipper Room and The Zipper Factory.  She started out as an actor, studying theater at Oberlin College, Meisner technique at Ward Studio, and improvisation at The Second City Training Center in New York. Connect with Erin https://www.hotterthaneverpod.com/ https://www.instagram.com/hotterthaneverpod   Connect with Reena bettercalldaddy.com linkedin.com/in/reenafriedmanwatts twitter.com/reenareena instagram.com/reenafriedmanwatts instagram.com/bettercalldaddypodcast Me and my dad would love to hear from you, Drop us a review, reviews help more people find the show, and let us know what you like and what you'd like us to change, Please share the show with one friend who you think would be helped by the show  ratethispodcast.com/bettercalldaddy podchaser.com/bettercalldaddy Castmagic is the AI tool I use for show notes and podcast title ideas, it has helped save me tons of time. I talked about it in this episode.  Please use my affiliate link if you sign up. https://get.castmagic.io/bettercalldaddy   PodKnow 2024 is happening on Saturday, February 17th, 2024 and will have 10 speakers on everything from podcast growth to monetization and more. Your podcast will definitely benefit from attending and getting all of the valuable information from experts in their fields of podcasting and online marketing. All speakers are successful in their areas! https://nycpodcastnetwork.com/podknow2024-bcd/   Are you a popular podcaster or a rising influencer? Or do you have a great idea for an online business? Then you should know that every great website starts with an awesome domain name. Namecheap offers hundreds of domain extensions, from the traditional dot com to creative extensions for podcasters like dot fm, dot live, or dot space.   Namecheap is the world's 2nd largest domain registrar, with nearly 17 million domains under management and a top web service provider for everything you need to launch an amazing website. Namecheap offers hundreds of domain extensions from the traditional .com to creative extensions like .fm, .live or .space  Namecheap is offering Better Call Daddy listeners 20% off any non-premium domain name for its first year of registration with the code REENA20. The offer cannot be combined with any existing sales but can override any current sale if its discount is less than 20%. The code is valid for all new and existing Namecheap customers. You can register up to 10 domains per account with this code.    To get a domain name with a 20% discount (including .com and 455 other extensions). Go to namecheap.com , search for your desired domain, and use the code REENA20 at checkout.    Better Call Daddy is hosted by Podbean if you are looking to start a podcast of your own you'll need a reliable host https://www.podbean.com/BetterCallDaddy

This week, Kara and Liza recap the episode “Breakwater” (Season 24, Episode 5). Plus, they discuss the Chicago Park District lifeguard sexual abuse scandal and the Paul Hickson rape cases.SOURCES:Cook County Sheriff's OfficeWBEZ 1WBEZ 2WBEZ 3WBEZ 4WBEZ 5WBEZ 6WBEZ 7WBEZ 8Chicago Sun-Times 1Chicago Sun-Times 2Chicago Sun-Times 3Chicago Sun-Times 4Chicago Sun-Times 5The IndependentThe HeraldWikipedia - Paul HicksonThe StatesmanWHAT WOULD SISTER PEG DO:Safe4AthletesNext week's episode will be “Baby Killer” (Season 2, Episode 5).See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

An Unexpected Road to Religion and Meaning  Breakwater Festival 2023 Paths, People & Places Posted here: https://www.youtube.com/@flowinthedarkproductions6449     Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/eex6RuVC https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://paulvanderklay.me/2019/08/06/converzations-with-pvk/ There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640

Today we are chatting with writer/director James Rowe about his new film BREAKWATER. BREAKWATER stars Dermot Mulroney and Darren Mann. It's a fantastic thriller with lots of twists and turns. Hosted by: Andrew Lamping and Jeff Stolhand Produced by: Melody Lopez Original Theme Music by: Stephen D. Bennett --- Send in a voice message: https://podcasters.spotify.com/pod/show/filmmakermixer/message

On CinemAddicts episode 221, we review the features The Mental State (2:12), A Creature Was Stirring (7:58), Breakwater (14:58), Freud's Last Session (23:11), and The Great Silence (31:24).For December's Patreon episode, we spotlight 1983 with reviews of The Keep and Eureka.Use our Amazon movie links or SiteStripe for your purchases to support CinemAddicts (we receive a slight commission)!**Check out our CinemAddicts podcast feed for previous episodes on Acast: https://shows.acast.com/cinemaddicts1. Subscribe to our CinemAddicts YouTube Channel.2. Like Our CinemAddicts Facebook Page3. Join our CinemAddicts Facebook Group for daily movie recommendations! 4. Questions/comments on CinemAddicts email Greg Srisavasdi at info@findyourfilm.com.5. Find CinemAddicts recaps and coverage on our website Find Your Film.6. Contact Bruce Purkey for some What's in the Box recommendations: brucepurkey@gmail.com7. Eric Holmes can be reached at hamslime@gmail.com and on X. 8. Anderson Cowan's latest project is Loaded for Bear: The Documentary. For info and support: https://loadedforbeardoc.com/ Hosted on Acast. See acast.com/privacy for more information.

Willow Kean does an winning monologue in studio, we hear from author Donna Morrissey, and publishers from three different publishing houses, Glenn Day from Boulder Books, Rebecca Rose from Breakwater Books, and Jerry Cranford from Flanker Press, join Krissy in studio. Recommended books from publishers include: Glenn Day from Boulder books tells us about their latest guide book "Beaches of Newfoundland" by Carla Smith Krachun. He also recommends Hidden Nova Scotia, a children's book called Walter & Seymore: Let's Play by Kim Osbourne, and The Grounds Café cook book. Then, Rebecca from Breakwater recommends Impressions of Newfoundland by Ting Ting Chen, Suliewey by Mi'sel Joe and Sheila O'Neill, Five for Forteau by Kevin Major, and A Company of Rogues by Trudy J. Morgan-Cole. For children's books, Rebecca recommends IsThisAnOlogy? by Amanda Dorothy Jean Bulman, and The Ewe Who Knew Who Knit You by Cara Kansala. Last, Jerry Cranford from Flanker Press recommends The World Search of Newfoundland and Labrador - Volume 2 - by Nick Cranford, Much More Than Police by Terry Carlson, Away From My Island by Gary Collins, We'd Rather Fight Than Eat by Jay McGrath, and The River Murder by Patrick J Collins.

Upcoming TLC Events Breakwater Festival Mannheim Germany October 27-29 2023 Event Details and Tickets: https://buytickets.at/breakwater/935800   T-shirts: https://buytickets.at/breakwater/store Discord: tinyurl.com/BreakwaterDiscord   Festival Email: contact.breakwater@gmail.com  Flyer https://bit.ly/breakwaterfestival2023  Convivium 2023: Poetry as Perception, November 17-18, Hector, AR https://events.eventzilla.net/e/convivium-2023-poetry-as-perception-2138588315 Join this channel to get access to perks: https://www.youtube.com/channel/UCGsDIP_K6J6VSTqlq-9IPlg/join   Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/nZADRwgy https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://paulvanderklay.me/2019/08/06/converzations-with-pvk/ There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640

Breakwaters ease the impact of large waves during storms, reducing shoreline erosion and damage. We learn about efforts to improve a Milwaukee breakwater, bolstering protection for the Harbor District.

This week's episode is a FUN one with Erin Keating who talks about her tips on being "Hotter Than Ever."  Erin tells the story about how she blew up her life at age 50 and started to reinvent herself to become a more authentic version of myself TODAY (rather just living in the results of the goals she had for myself and my life 20 years ago).  She also describes her unconventional dating "Rumspringa" the year following my separation (her year to explore and 'sow her wild oats'), and 4 things you can do to be Hotter than Ever.  Erin Keating is an award-winning television development and production executive and single Mom to twin tweens living in Los Angeles. Her podcast Hotter Than Ever reflects the authentic, messy, sexy, funny and inspiring stories of women over forty. Erin's passion for smart, brand-defining original programming has led to zeitgeist-shaping shows like Portlandia, along with the first-ever made-for-mobile scripted series.  Her career has included senior creative roles at Snapchat, Big Beach TV, IFC TV and Magna Global Entertainment.  She climbed the television ladder at BBC America, NBC and Comedy Central. Recent shows created under Erin's watch have included the Emmy-winning James Corden's Next James Corden, the WGA Award winning drama Class of Lies, the WGA Award nominated thriller Breakwater and the NAACP Image Award-nominated Two Sides. Erin also conceived the drama Vida (Starz), produced the documentary Fatherless (Fusion), and executived the hell out of the iconic sketch series Portlandia (which won a Peabody and a bunch of other fancy statues) along with other comedy, dramedy and animated series.  Erin grew up in the basement theaters of downtown NYC, where she produced and performed in live comedy shows at venues like The Slipper Room and The Zipper Factory.  She started out as an actor, studying theater at Oberlin College, Meisner technique at Ward Studio, and improvisation at The Second City Training Center in New York. Download this episode, share it on social, and sign up for our free newsletter by filling out any contact form on our site (www.smartdatingacademy.com).  Follow us on Instagram as well @smartdatingacademy! Fill out our podcast listener survey by putting this link into your browser:  https://www.smartdatingacademy.com/survey Follow us on Instagram at @smartdatingacademy Schedule your consultation with us here!   We are on a waiting list, and would love to help you!  https://www.smartdatingacademy.com/11-coaching/coaching-call-with-bela

The fellas drop in CoLab Public House in Vista, CA. The CoLab is a craft beer lovers paradise! No need to brew hoo here, you've got 3 solid breweries Breakwater, Barrel n Stave and Laguna Beer Co. And for the Wine lover you have Propaganda Wine Co. And did we mention Baby's Badass Burgers? Join us on this amazing episode! Special guests include Chris from Barrel and Stave and Joe from Propaganda! Cheers Everyone! Support the showHop Con 2023

The ACP team up with Tom Curry and look back on the last 8 years of the podcast. Books and moments are revisited, recommendations are laid down and tons of fun is had as the pod prepares for the next chunk of comic making years! Great stuff to check out this week - Tom Curry, Viz, Helen McCarthy, Leamington Comic Con, OK Comics, Mark Millar, Pat Mills, Awesome Comics, Infinite Kung Fu, Avery Hill, Follow Me In, Katriona Chapman, Breakwater, Porcelain, Snake Claws, Eternal, Outer Darkness, WIP Comics Anthology, Bette Noir, Andrew Clemson, Knave of Hearts, Sarah Webb, ACP recommends, Mobile Suit Gundam: The Origin, Jeff, Rising Sand, Dragons Claws, EJunkie Guardians of Pain, Jamie Me, B:Mecha

7 - 07 - 23 BLAKES NEVER ENDING PTOWN BREAKWATER WALK by Maine's Coast 93.1

Here are all the links for the festival:  Event Details and Tickets: https://buytickets.at/breakwater/935800     T-shirts: https://buytickets.at/breakwater/store  Discord: tinyurl.com/BreakwaterDiscord         Festival Email: contact.breakwater@gmail.com   Flyer https://bit.ly/breakwaterfestival2023   July Washington DC Event with Michael Martin and Spencer Klavan https://www.eventbrite.com/e/christ-and-community-in-the-modern-age-tickets-608591853617 Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/rpf3zatJ https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://paulvanderklay.me/2019/08/06/converzations-with-pvk/ There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640  

Shereen recaps some events in Palestine in 2022 that led to it being the deadliest year in the West Bank in decades. She also discusses Israel's far-right government and the recently-appointed ultranationalist ministers who will only take it further in that direction.See omnystudio.com/listener for privacy information.

Narrator: Abbe Opher